FindTrial
Sign In

Development and validation of a proteomics features based system to predict response to chemotherapy and immune therapy

Development and validation of a proteomics features based system to predict response to chemotherapy and immune therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061493
Enrollment
Unknown
Registered
2022-06-27
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Effiecacy group:None
Ineffiecacy group:None

Sponsors

First Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis of gastric cancer; 2. Perioperative therapy (chemotherapy and targeted and/or immunotherapy) is proposed.

Exclusion criteria

Exclusion criteria: 1. No previous history of other malignant tumors; 2. No serious underlying medical diseases, tolerant to chemotherapy, targeting and immunotherapy; 3. Refused to participate in the study.

Design outcomes

Primary

MeasureTime frame
Prediction accuracy for objective responce;—

Secondary

MeasureTime frame
Pathological response rate;R0 resection rate;Objective responce rate;Prediction accuracy for pathological response rate;—

Countries

China

Contacts

Public ContactZhao Qingchuan
zhaoqc@fmmu.edu.cn+86 29 84771503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026